Abstract
The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease. (Figure presented.)
Cite
CITATION STYLE
APA
Hunter, P. (2024). The controversy around anti-amyloid antibodies for treating Alzheimer’s disease: The European Medical Agency’s ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy. EMBO Reports, 25(12), 5227–5231. https://doi.org/10.1038/s44319-024-00294-4
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free